Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Gynecologic Oncology

• Publication date

  2009-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2009.06.011PMID 19592079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Uterine Papillary Serous Carcinoma

  2011cited by this paper
• A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.

  2009influential reference
• A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.

  2009cited by this paper
• Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

  2009cited by this paper
• Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

  2009cited by this paper
• Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.

  2009cited by this paper
• Chemotherapy With or Without Radiation Therapy Favorably Impacts Survival Outcomes in Stage I Uterine Papillary Serous Carcinoma

  2009cited by this paper
• Endometrial glandular dysplasia and endometrial intraepithelial neoplasia

  2008cited by this paper
• Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

  2008cited by this paper
• Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.

  2008cited by this paper
• Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

  2008cited by this paper
• Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype

  2008cited by this paper
• Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).

  2008cited by this paper
• Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.

  2008cited by this paper
• Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer

  2007cited by this paper
• Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.

  2007cited by this paper
• The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.

  2007cited by this paper
• Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors.

  2007cited by this paper
• Clinicopathologic Analysis of 187 High-grade Endometrial Carcinomas of Different Histologic Subtypes: Similar Outcomes Belie Distinctive Biologic Differences

  2007cited by this paper
• HER‐2/neu overexpression and amplification in uterine serous papillary carcinoma

  2007cited by this paper
• Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?

  2007cited by this paper
• Outcomes in surgical stage I uterine papillary serous carcinoma.

  2007cited by this paper
• Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus?

  2007cited by this paper
• Racial disparities in blacks with gynecologic cancers

  2007cited by this paper
• Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.

  2007cited by this paper
• Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

  2007cited by this paper
• The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.

  2007cited by this paper
• Occurrence of Endometrial Glandular Dysplasia Precedes Uterine Papillary Serous Carcinoma

  2007cited by this paper
• Serous carcinoma of the uterus—determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation

  2007cited by this paper
• Body size in relation to cancer of the uterine corpus in 1 million Norwegian women

  2007cited by this paper
• Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

  2007cited by this paper
• The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer.

  2006cited by this paper
• Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma

  2006cited by this paper
• Therapeutic role of lymph node resection in endometrioid corpus cancer

  2006cited by this paper
• Treatment of uterine papillary serous carcinoma with platinum‐based chemotherapy and paclitaxel

  2006cited by this paper
• Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers.

  2006cited by this paper
• Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group.

  2006cited by this paper
• The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.

  2006cited by this paper
• Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

  2006cited by this paper
• Molecular and pathologic aspects of endometrial carcinogenesis.

  2006cited by this paper
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

  2006cited by this paper
• HER‐2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications

  2006cited by this paper
• Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?

  2006cited by this paper
• Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.

  2005cited by this paper
• A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.

  2005cited by this paper
• Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management.

  2005cited by this paper
• Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study.

  2005cited by this paper
• Amplification of c‐erbB2 oncogene

  2005cited by this paper
• Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

  2005cited by this paper
• Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  2005cited by this paper
• The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).

  2005cited by this paper
• Minimal uterine serous carcinoma: a clinicopathological study of 40 cases

  2005influential reference
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy

  2005cited by this paper
• Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.

  2005cited by this paper
• Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.

  2005cited by this paper
• Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?

  2005cited by this paper
• Uterine papillary serous carcinoma: what have we learned over the past quarter century?

  2005cited by this paper
• Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.

  2005cited by this paper
• Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

  2004cited by this paper
• Optimal management for surgically Stage 1 serous cancer of the uterus.

  2004cited by this paper
• The role of optimal debulking in advanced stage serous carcinoma of the uterus.

  2004cited by this paper
• BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.

  2004cited by this paper
• Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival.

  2004cited by this paper
• The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma.

  2004cited by this paper
• HIGH-DOSE RATE BRACHYTHERAPY FOR STAGE I/II PAPILLARY SEROUS OR CLEAR CELL ENDOMETRIAL CANCER

  2004cited by this paper
• Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

  2004cited by this paper
• Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2004cited by this paper
• Endometrial Glandular Dysplasia: A Newly Defined Precursor Lesion of Uterine Papillary Serous Carcinoma. Part I: Morphologic Features

  2004cited by this paper
• Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.

  2004cited by this paper
• Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.

  2004cited by this paper
• Uterine serous and grade 3 endometrioid carcinomas

  2004cited by this paper
• Association between uterine serous carcinoma and breast cancer.

  2004cited by this paper
• Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.

  2003influential reference
• Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.

  2003cited by this paper
• Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus

  2003cited by this paper
• Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

  2003cited by this paper
• Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.

  2003cited by this paper
• Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

  2003cited by this paper
• Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.

  2003cited by this paper
• Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.

  2003cited by this paper
• Uterine papillary serous carcinomas: the exigency for clinical trials.

  2003cited by this paper
• Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy.

  2003cited by this paper
• Uterine serous carcinoma: a comparison of therapy for advanced-stage disease

  2003cited by this paper
• Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.

  2003cited by this paper
• Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

  2002cited by this paper
• Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?

  2002cited by this paper
• FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival

  2002cited by this paper
• Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study.

  2002cited by this paper
• The role of omentectomy during the surgical staging of uterine serous carcinoma

  2002cited by this paper
• Overexpression of HER-2/neu in uterine serous papillary cancer.

  2002cited by this paper
• Treatment of uterine papillary serous carcinoma with paclitaxel.

  2001cited by this paper
• Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

  2001cited by this paper
• Noninvasive Papillary Serous Carcinoma of the Endometrium

  2001cited by this paper
• Risk of endometrial carcinoma associated with BRCA mutation.

  2001cited by this paper
• Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma.

  2001cited by this paper

• Guidelines for radiation therapy for endometrial cancer by Brachytherapy Committee of China Anti-Cancer Association (V 2025.1)

  2025cites this paper
• ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

  2025cites this paper
• A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma

  2025cites this paper
• Modifying surgical extents in patients with preoperatively presumed early-stage endometrial cancer based on ProMisE classification: a retrospective, single-center study

  2025cites this paper
• Omentectomy for apparent early-stage uterine serous carcinoma: a large retrospective cohort study

  2025cites this paper
• The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases

  2024cites this paper
• Adjuvant Treatment of Stage I–II Serous Endometrial Cancer: A Single Institution 20-Year Experience

  2024cites this paper
• Exploring the protein signature of endometrial cancer: A comprehensive review through diverse samples and mass spectrometry-based proteomics.

  2024cites this paper
• Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

  2023cites this paper
• A nomogram for predicting overall survival in patients with type II endometrial carcinoma: a retrospective analysis and multicenter validation study.

  2023cites this paper
• A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer

  2023cites this paper
• A nomogram for predicting cancer-specific survival in patients with uterine clear cell carcinoma: a population-based study

  2023cites this paper
• Serous endometrial intra-epithelial carcinoma: an observational study

  2023cites this paper
• The clinico pathological features and survival in serous endometrial cancers

  2023cites this paper
• Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study

  2023cites this paper
• Effects of Adjuvant Radiation Plus Chemotherapy on Survival Outcomes in Stage III C Endometrial Cancer According to Histology: Analysis of Data from the Surveillance, Epidemiology, and End Results Database

  2023cites this paper
• Systematic Lymphadenectomy and Oncological Outcomes of Women With Apparent Early-Stage Clear Cell Carcinoma of the Endometrium: A Multi-Institutional Cohort Study

  2022cites this paper
• Endometrial Polyp in Postmenopausal Women.

  2022cites this paper
• Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study

  2022cites this paper
• Prognostic features of endometrial cancer metastasis to the central nervous system

  2022cites this paper
• Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities.

  2022cites this paper
• Executive Summary of the Uterine Cancer Evidence Review Conference

  2022cites this paper
• Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis.

  2022cites this paper
• Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.

  2022cites this paper
• Factor affecting lymph node metastasis in uterine papillary serous carcinomas: a retrospective analysis

  2022cites this paper
• Executive summary of the American Radium Society appropriate use criteria for management of uterine clear cell and serous carcinomas

  2022cites this paper
• Interdisciplinary approach to the management of patients with uterine cancer progression

  2022cites this paper
• Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes

  2021cites this paper
• Sexual Function in Women Undergoing Risk Reducing Salpingo-Oophorectomy With or Without Hysterectomy

  2021cites this paper
• Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique

  2021cites this paper
• The current evidence for the use of minimally-invasive surgery in endometrial cancer

  2021cites this paper
• Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma

  2021cites this paper
• Controversies in the Management of Early-stage Serous Endometrial Cancer

  2021cites this paper
• Matched-pair Analysis for Survival Endpoints Between Women With Early-stage Uterine Carcinosarcoma and Uterine Serous Carcinoma

  2021cites this paper
• What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience

  2021cites this paper
• The Advantage of Pinpoint Camera System With Indocyanine Green for Sentinel Lymph Node Micrometastasis Detection in Low Risk Endometrial Cancer

  2021cites this paper
• Detection of bone metastases in uterine cancer: How common are they and should PET/CT be the standard for diagnosis?

  2021cites this paper
• The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study.

  2021cites this paper
• Minimal Uterine Serous Carcinoma and Endometrial Polyp: A Close Clinicopathological Relationship.

  2021cites this paper
• Serous endometrial intraepithelial carcinoma (SEIC): Current clinical practice in The Netherlands.

  2021influential citation
• Rare brain metastasis with unusual characteristics in a late recurrence of stage IIIA uterine papillary serous carcinoma

  2021cites this paper
• Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center.

  2021cites this paper
• Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

  2021cites this paper
• Positron Emission Tomography (PET)

  2021cites this paper
• Adjuvant vaginal interventional radiotherapy in early-stage non-endometrioid carcinoma of corpus uteri: a systematic review

  2021cites this paper
• Is there a benefit of performing an omentectomy for clinical stage I high-grade endometrial carcinoma?

  2021cites this paper
• Pathology findings among women with alterations in uterine bleeding patterns in cameroon

  2021cites this paper
• Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification

  2021cites this paper
• Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer

  2021cites this paper
• Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.

  2021cites this paper
• Clinicopathological characteristics and prognosis of uterine serous carcinoma: A SEER program analysis of 1016 cases

  2021cites this paper
• Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

  2020cites this paper
• Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium

  2020cites this paper
• Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands

  2020cites this paper
• Recent Advances in Endometrial Cancer

  2020cites this paper
• The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review

  2020cites this paper
• Getting serious about serous endometrial cancer: should we give chemotherapy in non-invasive cases?

  2020cites this paper
• Histo-Epidemiological Profile of Endometrial Cancer in the Oran Region

  2020cites this paper
• Changing Trends in the Epidemiology of Endometrial Cancer

  2020cites this paper
• Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: an ENITEC collaboration study

  2020cites this paper
• Oncological Surgical Pathology

  2020cites this paper
• Comprehensive lymphadenectomy and survival prediction in uterine serous cancer patients after surgery: A population-based analysis.

  2020cites this paper
• Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus

  2020cites this paper
• Potential Factors Associated with Pelvic Lymph Node Metastasis in Endometrioid Endometrial Carcinoma

  2020cites this paper
• xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma

  2020cites this paper
• Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.

  2020cites this paper
• Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

  2020cites this paper
• High risk endometrial cancer: clues towards a revision of the therapeutic paradigm.

  2019cites this paper
• External Beam, Brachytherapy, or Chemotherapy? Defining Adjuvant Therapy for Early-Stage and High- and High-Intermediate-Risk Endometrial Cancer.

  2019cites this paper
• Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.

  2019cites this paper
• Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site

  2019cites this paper
• Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019

  2019cites this paper
• Endometrial Cancer: An Overview of Pathophysiology, Management, and Care.

  2019cites this paper
• Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens

  2019cites this paper
• Uterine Papillary Serous Carcinoma Arising in a Polyp: A Multicenter Retrospective Analysis on 75 Patients

  2019cites this paper
• A novel model to predict cancer‐specific survival in patients with early‐stage uterine papillary serous carcinoma (UPSC)

  2019cites this paper
• National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.

  2019cites this paper
• In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.

  2019cites this paper
• Prognostic factors impacting survival in early stage uterine carcinosarcoma.

  2019cites this paper
• Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma.

  2019cites this paper
• Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study

  2019cites this paper
• Distant recurrence in a patient with polyp-confined stage IA serous endometrial carcinoma treated with adjuvant chemotherapy: A case report and review of literature

  2019cites this paper
• Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: an ENITEC collaboration study.

  2019cites this paper
• The role of omentectomy in the surgical treatment of uterine serous carcinoma

  2019cites this paper
• FDG-PET for Assessment of Endometrial and Vulvar Cancer.

  2019cites this paper
• Cancer antigen 125 is associated with disease status in uterine carcinosarcoma

  2019cites this paper
• Endometrial Cancer

  2019cites this paper
• Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma

  2019influential citation
• The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression

  2019cites this paper
• Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma

  2019cites this paper
• Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

  2018cites this paper
• Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma

  2018cites this paper
• Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma

  2018cites this paper
• Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.

  2018cites this paper
• Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response

  2018cites this paper
• Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer

  2018cites this paper
• Hysterectomy at the time of risk-reducing surgery in BRCA carriers

  2018cites this paper
• Prognostic Factors of Uterine Serous Carcinoma—A Multicenter Study

  2018cites this paper
• SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.

  2018cites this paper
• Survival implications of staging lymphadenectomy for non-endometrioid endometrial cancers.

  2018cites this paper